Komori
Business alliance4890Tsubota Laboratory IncorporatedPharmaceuticals

Notice Regarding the Achievement of the Final Milestone and Recognition of Revenue Under a License Agreement with an Overseas Pharmaceutical Company

Under the license agreement with an overseas pharmaceutical company, disclosure and acceptance of the final data have been completed, and the final milestone has been achieved. The related revenue is scheduled to be recognized in the first quarter of the fiscal year ending March 2027.

Worth reading
35Immaterial
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Impact on Business Performance

The impact on the current fiscal year's earnings forecast is minor. The revenue has already been included in the earnings forecast for the fiscal year ending March 2027.

Contract Date15 October 2024
Agreements reached under this partnership
ItemDetails
Contract Date15 October 2024
Impact on Business PerformanceThe impact on the current fiscal year's earnings forecast is minor. The revenue has already been included in the earnings forecast for the fiscal year ending March 2027.
Items this document does not state (21)
Name of alliance partnerAlliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Development by the overseas pharmaceutical company has progressed, and disclosure and acceptance of the final data under the agreement have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Achievement of the Final Milestone and Recognition of Revenue Under a License Agreement with an Overseas Pharmaceutical Company | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori